Seroconversion Following COVID-19 Vaccination in Patients with Multiple Myeloma (MyVax)


In this study, patients with multiple myeloma will be tested to see how well the vaccine against COVID-19 has worked. It is recommended that all patients with myeloma receive a vaccine against COVID-19 after discussing this with their physician. But there is very little information available about how well COVID-19 vaccines work in patients with myeloma. Myeloma patients can have decreased immune function and in the effectiveness of vaccines due to the disease and the treatments that patients receive.

This study will include patients with multiple myeloma who plan to be vaccinated for COVID-19 or who have recently been vaccinated. It will look for the antibodies that develop in response to COVID-19 vaccine or infection. A blood sample looking for antibodies against COVID-19 will be taken before the first dose of vaccine, and again 4 weeks after vaccination is complete. If antibodies are found, participants will be retested after 3 months and 6 months to see how long the antibodies last.


Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 18 to 100

Inclusion criteria:

To be included, participants will:
1. Be at least 18 years old
2. Have with a diagnosis of multiple myeloma, smoldering myeloma, or systemic amyloidosis
3. Have received or plan to receive a vaccine for COVID-19.

Exclusion criteria:

Patients will not be eligible if they are unable to have complete course of vaccination, or cannot receive a COVID-19 vaccine for any reason.


Fill out the following form if you want to participate in this research

Method of contact

Additional information

Contact information

Patients can be referred to this study by their physician or by contacting Dr. Peter Duggan

Principal investigator:

Peter Duggan

Clinical trial: